Background: In 2020, melanoma exhibited the 5th highest incidence rate of all cancers in the US. While metastatic melanoma constitutes only 4% of new melanoma cases, the 5-year survival rate of metastatic melanoma is 27% [1]. Immune Checkpoint Inhibitors (ICIs) were the first drugs to significantly improve the 5-year survival of late-stage melanoma patients; these […]

Case Presentation: A 67-year-old woman with a history of metastatic squamous cell carcinoma of the lungs and plaque psoriasis presented with subacute pruritic and painful descaling lesions of the skin after pembrolizumab maintenance therapy (Figure 1.A). The lesions on the skin were erythematous and desquamating, worse in the upper extremities, lower extremities, abdomen, and trunk. […]

Case Presentation: An 81-year-old man with a history of paroxysmal atrial fibrillation and angiosarcoma on immunotherapy presented with acute onset of shortness of breath, chest pressure and lower extremity edema. He had been started on ipilimumab and nivolumab 1 year prior to presentation and had developed immune checkpoint inhibitor (ICI) thyroiditis, hepatitis, and pneumonitis while […]

Case Presentation: Immune checkpoint inhibitors have evolved into the conventional therapy regimen for many cancer types. The major categories of immune checkpoint inhibitors include monoclonal antibodies against cytotoxic T lymphocyte antigen (CTLA-4), programmed cell death protein-1 (PD-1) and programmed cell death ligand molecules (PD-L1). Pembrolizumab has been implicated in causing hepatitis Discussion: An 89-year-old Caucasian […]

Case Presentation: This is a case of a 72-year-old male with Stage III metastatic melanoma. The patient was started on combination immunotherapy with ipilimumab and nivolumab three months prior. He completed three cycles of treatment. He presented to the emergency department with complaints of fatigue and lethargy. Initial assessment of vitals showed hypotension, BP 95/61 […]

Case Presentation: 56-year-old Caucasian lady with a past medical history of recurrent stage 4 melanoma presented with nausea, vomiting, inadequate oral intake and weight loss of 20lbs over several weeks. She received nivolumab immunotherapy for one year and stopped 3-months prior to presentation due to stable lesions without recurrence. She also underwent an esophagogastroduodenoscopy (EGD) […]